Fluocortolone

Fluocortolone

SCHEMBL3047399

CC1C[C@H]2[C@@H]3CC(F)C4=CC(=O)C=C[C@]4(C)[C@H]3C(O)C[C@]2(C)[C@H]1C(=O)CO

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 9/20 0.70
AR P10275 6/20 0.70
ADRA1A P35348 2/20 0.70
CHRM1 P11229 2/20 0.70
ADORA3 P0DMS8 2/20 0.70
SLC6A2 P23975 1/20 0.70
SLC6A3 Q01959 1/20 0.70
KCNH2 Q12809 1/20 0.70
NR1I2 O75469 3/20 0.61
HTR2B P41595 1/20 0.61
CYP3A4 P08684 7/20 0.56
NR3C1 P04150 6/20 0.56
ABCB11 O95342 5/20 0.56
HSD17B10 Q99714 2/20 0.56
LMNA P02545 2/20 0.56
KDM4E B2RXH2 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
HIF1A Q16665 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluocortolone SCHEMBL21706397 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL4644 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL11518086 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL11862489 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL19327147 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL13902941 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL11333890 1.00 PGR (0.70) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL144059 0.99 PGR (0.69) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL21852268 0.98 PGR (0.68) PGRARADRA1ACHRM1ADORA3
Fluocortolone SCHEMBL3690986 0.97 PGR (0.67) PGRARADRA1ACHRM1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP claimed
EP-2181704-A2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2010-05-05 EP claimed
EP-1594459-B1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INT AG (CH) 2010-02-17 EP claimed
US-20070021360-A1 Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase EPIGENESIS PHARMACEUTICALS, LLC 2007-01-25 US claimed
EP-1448202-A1 COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA Pharma AG (DE) 2004-08-25 EP claimed
WO-2003039552-A1 COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA PHARMA AG (DE) 2003-05-15 WO claimed
US-20030092706-A1 Combination NYCOMED GMBH (DE) 2003-05-15 US claimed
EP-0374185-B1 IMPROVED 9$g(a)-DEHALOGENATION PROCESS THE UPJOHN COMPANY (US) 1993-02-10 EP claimed
US-4704358-A Δ1 -dehydrogenation with heat or air-dried B. cyclooxidans THE UPJOHN COMPANY (US) 1987-11-03 US claimed
US-4524134-A BIOCONVERSION WITH ARTHROBACTER SIMPLEX THE UPJOHN COMPANY (US) 1985-06-18 US claimed
US-4011317-A STEROID DERIVATIVES RORER ITALIANA S.P.A. (IT) 1977-03-08 US claimed
US-11913031-B2 Method to reproduce circadian rhythms on a microfluidic chip YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-02-27 US disclosed
US-20200318077-A1 METHOD TO REPRODUCE CIRCADIAN RHYTHMS ON A MICROFLUIDIC CHIP YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2020-10-08 US disclosed
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
US-4170518-A Microbiological conversion of sterol derivatives to 5-androsten-17-one derivatives and their use SCHERING AKTIENGESELLSCHAFT (DE) 1979-10-09 US disclosed
US-4017615-A ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS SYNTEX CORPORATION (PM) 1977-04-12 US disclosed
US-3984544-A Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor SCHERING CORPORATION (US) 1976-10-05 US disclosed
US-3956347-A Novel pregnanoic acid derivatives SCHERING AKTIENGESELLSCHAFT (DT) 1976-05-11 US disclosed
US-3935245-A DIAGNOSTIC SCHERING AKTIENGESELLSCHAFT (DT) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021360-A1 Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase RECQL, GSS, DDX17 PGR 965/4885AR 209/4885ADRA1A 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.